{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:07:09Z","timestamp":1771657629249,"version":"3.50.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Little is known about the distribution of hepatitis C virus (HCV) genotypes among people who inject drugs (PWID) in North African countries, including Tunisia. This study aims to describe HCV genotypes circulating among Tunisian PWID. A cross-sectional study was conducted, and 128 HCV-positive PWID were recruited between 2018 and 2019 from community-based harm reduction centers. After informed consent, sociodemographic characteristics and risk behavior data were obtained using an interviewer-administrated questionnaire. Blood samples were collected for further serological and molecular testing. Overall, five women and 123 men were included. The median age was 39.5 years. The majority of PWID (56.3%) had less than a secondary level of education, were single (57%), were unemployed (65.6%), were incarcerated at least once (93.0%), and had a history of residency in at least one foreign country (50.8%). During the previous 12 months, 82.0% reported having reused syringes at least once, 43.8% shared syringes at least once, while 56.2% had at least one unprotected sexual relation, and 28.1% had more than two different sexual partners. Tattooing was reported among 60.2%. All positive results for HCV-infection by rapid testing were confirmed by enzyme-linked immunosorbent assay (ELISA). HCV-RNA was detectable in 79.7%. Genotyping showed a predominance of genotype 1 (52%) followed by genotype 3 (34%) and genotype 4 (10%). Four patients (4%) had an intergenotype mixed infection. Subtyping showed the presence of six different HCV subtypes as follows: 1a (53.2%), 1b (6.4%), 3a (33.0%), 4a (3.2%), and 4d (4.3%). This is the first study describing circulating HCV genotypes among PWID in Tunisia. The distribution of HCV genotypes is distinct from the general population with a predominance of subtypes 1a and 3a. These findings can be used to guide national efforts aiming to optimize the access of PWID to relevant HCV prevention and treatment measures including pangenotypic regimens for patients infected with HCV genotype 3.<\/jats:p>","DOI":"10.3389\/fmicb.2021.697859","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:59:25Z","timestamp":1627372765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal"],"prefix":"10.3389","volume":"12","author":[{"given":"Anissa","family":"Chouikha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Ghrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira","family":"Ghodbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Hammemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Khedhiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Sadraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henda","family":"Touzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hichem Ben","family":"Hassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Maatoug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaima","family":"Bensaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Abdelhak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Bouarrouj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariem","family":"Gdoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedia","family":"Chaouachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henda","family":"Triki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4176\/080425","article-title":"Risk factors and genotypes of hepatitis C virus infection in libyan patients.","volume":"3","author":"Alashek","year":"2008","journal-title":"Libyan J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV Genotype 3 \u2013 the new treatment challenge.","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B3","first-page":"458","article-title":"New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection.","volume":"11","author":"Ara","year":"2015","journal-title":"Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jviromet.2017.08.001","article-title":"Performance of rapid diagnostic tests for detection of Hepatitis B and C markers in HIV infected patients.","volume":"248","author":"Barbosa","year":"2017","journal-title":"J. Virol. Methods"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00705-019-04308-8","article-title":"Hepatitis C virus epidemiology in central-west tunisia: a population-based cross-sectional study.","volume":"164","author":"Bettaieb","year":"2019","journal-title":"Arch. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.drugalcdep.2017.04.003","article-title":"Belgian experience with direct acting antivirals in people who inject drugs.","volume":"177","author":"Bielen","year":"2017","journal-title":"Drug Alcohol. Depend."},{"key":"B7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic Hepatitis C.","volume":"51","author":"Bochud","year":"2009","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-2893.2002.00319.x","article-title":"Epidemiological changes in hepatitis C virus genotypes in france: evidence in intravenous drug users.","volume":"9","author":"Bourli\u00e8re","year":"2002","journal-title":"J. Viral Hepat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3748\/wjg.v24.i27.3038","article-title":"Systematic overview of Hepatitis C infection in the middle East and North Africa.","volume":"24","author":"Chaabna","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00705-020-04918-7","article-title":"Focus on Hepatitis C virus genotype distribution in tunisia prior to elimination: a 16-year retrospective study.","volume":"166","author":"Chouikha","year":"2021","journal-title":"Arch. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/s2468-1253(17)30086-9","article-title":"Rapid HCV RNA testing: removing the final obstacle to elimination.","volume":"2","author":"Cooper","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrgastro.2015.36","article-title":"Mixed HCV infection and reinfection in people who inject drugs\u2013impact on therapy.","volume":"12","author":"Cunningham","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Global Health"},{"key":"B14","first-page":"473","article-title":"Genetic variability of Genotype 1 Hepatitis C virus isolates from Tunisian haemophiliacs.","volume":"31","author":"Djebbi","year":"2008","journal-title":"New Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1023\/b:ejep.0000032348.83087.01","article-title":"Phylogenetic analysis of Hepatitis C virus isolates from Tunisian patients.","volume":"19","author":"Djebbi","year":"2004","journal-title":"Eur. J. Epidemiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1017\/s095026880300846x","article-title":"Genotypes of Hepatitis C virus circulating in Tunisia.","volume":"130","author":"Djebbi","year":"2003","journal-title":"Epidemiol. Infect."},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-6847-5","article-title":"The distribution and socioeconomic burden of Hepatitis C Virus in South Australia: a cross-sectional study 2010\u20132016.","volume":"19","author":"Edmunds","year":"2019","journal-title":"BMC Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on treatment of Hepatitis C 2018.","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/jmv.23643","article-title":"Hepatitis C virus Infection in the maghreb region.","volume":"85","author":"Ezzikouri","year":"2013","journal-title":"J. Med. Virol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121873","article-title":"The epidemiology of Hepatitis C Virus in the maghreb region: systematic review and meta-analyses.","volume":"10","author":"Fadlalla","year":"2015","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the Hepatitis C virus infection.","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.3748\/wjg.v23.i20.3569","article-title":"Hepatitis C in injection drug users: it is time to treat.","volume":"23","author":"Grassi","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?","volume":"20","author":"Grebely","year":"","journal-title":"J. Int. AIDS Soc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s2468-1253(17)30075-4","article-title":"Evaluation of the Xpert HCV viral load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.","volume":"2","author":"Grebely","year":"","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of Hepatitis C infection among people who have recently injected drugs.","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7448\/ias.19.1.20873","article-title":"Status of HIV and Hepatitis C virus infections among prisoners in the middle East and North Africa: review and synthesis.","volume":"19","author":"Heijnen","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0140-6736(16)30769-3","article-title":"Prevention of transmission of HIV, Hepatitis B Virus, Hepatitis C Virus, and Tuberculosis in prisoners.","volume":"388","author":"Kamarulzaman","year":"2016","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV Genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/molbev\/msw054","article-title":"MEGA7: molecular evolutionary genetics analysis Version 7.0 for bigger datasets.","volume":"33","author":"Kumar","year":"2016","journal-title":"Mol. Biol. Evol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"Incidence and prevalence of Hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis.","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and Hepatitis C among people who inject drugs: a systematic review.","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Global Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.","volume":"25","author":"MacArthur","year":"2014","journal-title":"Int. J. Drug Policy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210556","article-title":"Evaluation of five rapid diagnostic tests for detection of antibodies to Hepatitis C Virus (HCV): a step towards scale-up of HCV screening efforts in India.","volume":"14","author":"Mane","year":"2019","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.","volume":"57","author":"Martin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cgh.2016.10.012","article-title":"Infection with Hepatitis C Virus Genotype 3 is an independent risk factor for end-stage liver disease, Hepatocellular Carcinoma, and liver-related death.","volume":"15","author":"McMahon","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jmv.20342","article-title":"Contrasting patterns of Hepatitis C Virus infection in two regions from Tunisia.","volume":"76","author":"Mejri","year":"2005","journal-title":"J. Med. Virol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection.","author":"Midgard","year":"2016","journal-title":"J. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/qai.0b013e318284714a","article-title":"New evidence on the HIV epidemic in libya: why countries must implement prevention programs among people who inject drugs.","volume":"62","author":"Mirzoyan","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B39","first-page":"39","article-title":"Illicit use of high-dosage buprenorphine in Tunisia.","volume":"17","author":"Mosbah","year":"2018","journal-title":"Afr. J. Drug Alcohol Stud."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J. Viral. Hepat"},{"key":"B41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/clep.s43926","article-title":"Socioeconomic status in HCV infected patients - risk and prognosis.","volume":"5","author":"Omland","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","article-title":"Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.","volume":"105","author":"Palmateer","year":"2010","journal-title":"Addiction."},{"key":"B43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jvh.12501","article-title":"Performance of rapid diagnostic tests for the detection of antibodies to Hepatitis C Virus in whole blood collected on dried blood spots.","volume":"23","author":"Poiteau","year":"2016","journal-title":"J. Viral Hepat."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9060432","article-title":"Systematic review and meta-analysis of global prevalence of HBsAg and HIV and HCV antibodies among people who inject drugs and female sex workers.","volume":"9","author":"Rashti","year":"2020","journal-title":"Pathogens"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/s0140-6736(16)30379-8","article-title":"Clinical care of incarcerated people with HIV, viral Hepatitis, or Tuberculosis.","volume":"388","author":"Rich","year":"2016","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jhep.2016.07.042","article-title":"Global Genotype Distribution of Hepatitis C Viral Infection among People Who Inject Drugs.","volume":"65","author":"Robaeys","year":"2016","journal-title":"J. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"10811","DOI":"10.3748\/wjg.v21.i38.10811","article-title":"Injecting drug use: a vector for the introduction of new Hepatitis C virus genotypes.","volume":"21","author":"Ruta","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102734","article-title":"Evaluation of the Xpert HCV VL fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain.","volume":"80","author":"Saludes","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"B49","first-page":"531","article-title":"The profile of drug users in tunisia: implications for prevention.","volume":"94","author":"Sellami","year":"2016","journal-title":"La Tunisie Medicale"},{"key":"B50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jcv.2009.04.022","article-title":"Changes in the prevalence of Hepatitis c virus genotype among italian injection drug users\u2014relation to period of injection started.","volume":"45","author":"Sereno","year":"2009","journal-title":"J. Clin. Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcv.2019.02.005","article-title":"Performance of a rapid diagnostic test for screening of Hepatitis C in a real-life prison setting.","volume":"113","author":"Sharafi","year":"2019","journal-title":"J. Clin. Virol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"558","DOI":"10.7326\/0003-4819-157-8-201210160-00006","article-title":"Accuracy of rapid and point-of-care screening tests for Hepatitis C: a systematic review and meta-analysis.","volume":"157","author":"Shivkumar","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"B53","year":"2015","journal-title":"Actualisation des Recommandations du Traitement de L\u2019h\u00e9patite Virale C en Collaboration Entre la STGE et la STPI"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422x-11-43","article-title":"The \u2018hidden\u2019 epidemic: a snapshot of moroccan intravenous drug users.","volume":"11","author":"Trimbitas","year":"2014","journal-title":"Virol. J."},{"key":"B55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1574-695X.2011.00828.x","article-title":"Rapid detection of Hepatitis C Virus RNA by a reverse transcription loop-mediated isothermal amplification assay.","volume":"63","author":"Wang","year":"2011","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C virus infection epidemiology among people who inject drugs in europe: a systematic review of data for scaling up treatment and prevention.","volume":"9","author":"Wiessing","year":"2014","journal-title":"PLoS One"},{"key":"B57","year":"2012","journal-title":"MENAHRA\u2013The Middle East and North Africa Harm Reduction Association Best Practices in Strengthening Civil Society\u2019s Role in Delivering Harm Reduction Services."},{"key":"B58","year":"2016","journal-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis."},{"key":"B59","year":"2017","journal-title":"Global Hepatitis Report 2017."},{"key":"B60","year":"","journal-title":"Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection."},{"key":"B61","year":"","journal-title":"Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low-and Middle-Income Countries."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16132345","article-title":"Factors correlating to the development of Hepatitis C virus infection among drug users-findings from a systematic review and meta-analysis.","volume":"16","author":"Zhou","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic Hepatitis C virus infection: a systematic literature review and meta-analysis.","volume":"18","author":"Zoratti","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.697859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:59:40Z","timestamp":1627372780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.697859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":63,"alternative-id":["10.3389\/fmicb.2021.697859"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.697859","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"article-number":"697859"}}